TG

Tredegar Corporation 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended September 30, 2003. Tredegar Corporation operates primarily through three segments: Film Products, Aluminum Extrusions, and Therics (biotechnology). The company recently exited its venture capital investment activities, reporting them as discontinued operations, and suspended efforts to divest its Therics subsidiary, opting instead to support a new product rollout in 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Discontinued Operations: The nine-month net loss of $35.7M was driven primarily by a $49.2M after-tax loss on the sale of the venture capital investment portfolio. Excluding discontinued operations, the company generated $13.0M in net income from continuing operations.
• Revenue Decline: Sales decreased 2.8% year-over-year for the nine months, attributed to lower volumes in Film Products and Aluminum Extrusions.
• Margin Compression: Gross profit margins declined to 15.5% (9M 2003) from 20.4% (9M 2002). Drivers included the loss of domestic backsheet business with P&G, higher raw material and energy costs, and foreign currency headwinds (Canadian Dollar appreciation).
• Restructuring Charges: The company incurred $9.9M in charges for plant shutdowns, asset impairments, and restructurings in the first nine months of 2003, compared to $1.4M in the prior year. Significant items included a $2.7M charge related to the Therics facility sublease and $1.9M in asset impairments for Film Products.
• Debt Reduction: Total debt decreased from $259.3M (average Q3 2002) to $217.1M (Sept 30, 2003), with interest expense dropping to $5.0M for the nine months.

Guidance, Outlook, and Risks

• Therics Strategy: Management decided to support the 2004 rollout of a new line of orthopaedic products rather than divest. Near-term operating losses are expected to remain around $3M per quarter, with revenue generation anticipated in the first half of 2004.
• Film Products: Operating profit is expected to remain near Q3 levels in Q4 and gradually improve in 2004. The segment faces challenges from resin price increases and the loss of P&G business, though non-P&G products now comprise ~90% of revenue.
• Aluminum Extrusions: Profits are pressured by higher energy/insurance costs and currency fluctuations. Q4 profits are not expected to improve over year-ago levels due to seasonal weakness and declining customer orders.
• Liquidity: On October 17, 2003, the company refinanced debt with a new $250M credit agreement ($175M revolver, $75M term loan). The revolver capacity is reduced by $50M upon receipt of expected $54.4M in income tax recoveries (mid-2004).
• Risks: Key risks include dependency on P&G (33% of 2002 sales), inability to pass through raw material/energy cost increases, and the uncertainty of Therics' product commercialization and regulatory approval.

Investor Verification Checklist

• Tax Recovery Timing: Verify the receipt of the expected $54.4M income tax recovery in mid-2004, which impacts liquidity and debt covenant calculations.
• Therics Milestones: Monitor the progress of the new orthopaedic product line launch in 2004 and associated cash burn rates.
• P&G Exposure: Assess the long-term impact of the loss of domestic backsheet business on Film Products' volume and fixed cost absorption.
• Raw Material Costs: Track polyethylene/polypropylene resin and aluminum ingot prices to evaluate margin recovery potential.
• Debt Covenants: Review the leverage ratio (currently 1.96x pro forma) against the 3.0x maximum permitted under the new credit agreement.